Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: A Diverse Array Of Approvals, A CRL For Evolus' Botox Competitor, And Coherus Refiles Neulasta Biosimilar

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
Allergan Aesthetic Medicines Head Moatazedi Moves To Emerging Competitor Evolus
Teva Pushes CGRP Timeline Back To End Of 2018
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
Opioid Withdrawal Symptom Mitigation Data Can Support A Labeling Claim
Lofexidine Gets US FDA Panel Nod For Mitigating Opioid Withdrawal Symptoms
US WorldMeds' Opioid Withdrawal Drug Lofexidine Heads To US FDA Panel
Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts